Cartier Esham’s Testimony to Energy and Commerce Health Subcommittee on Treatments and Cures for Neurodegenerative Diseases
July 30, 2021
BIO regularly publishes reports that help us assess the health of the biopharmaceutical pipeline across different diseases so that we can identify and remove barriers to providing next generation cures and treatments to patients and their families. I will highlight three such analyses with a focus on neurology clinical development programs (pipeline, investment and clinical trial success rates) with the goal of providing helpful insights to this important conversation. Later I will do a deeper dive into Alzheimer’s Disease as an example of the state of innovation for neurodegenerative diseases.
Download Full Comments Below
Testimony to Energy and Commerce Health Subcommittee on Treatments and Cures for Neurodegenerative Diseases
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
BIO regularly publishes reports that help us assess the health of the biopharmaceutical pipeline across different diseases so that we can identify and remove barriers to providing next generation cures and treatments to patients and their families. I will highlight three such analyses with a focus on neurology clinical development programs (pipeline, investment and clinical trial success rates) with the goal of providing helpful insights to this important conversation. Later I will do a deeper dive into Alzheimer’s Disease as an example of the state of innovation for neurodegenerative diseases.